Clinical pharmacokinetics of alprazolam. Therapeutic implications.
about
Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metaboliteThe CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.The effect of alprazolam on acoustic stapedius reflex thresholds in healthy volunteersA new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data.Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant usersGABAergic modulation of human social interaction in a prisoner's dilemma model by acute administration of alprazolam.Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidinePharmacokinetics in lactating women: prediction of alprazolam transfer into milk.Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activityUse of alprazolam to facilitate mare-foal bonding in an aggressive postparturient mare.Low Doses of Ethanol Enhance LTD-like Plasticity in Human Motor Cortex.Drugs as CYP3A probes, inducers, and inhibitors.The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.A comparative study to assess the effect of oral alprazolam as premedication on vital parameters of patients during surgical removal of impacted mandibular third molars.Deleterious effects of a low amount of ethanol on LTP-like plasticity in human cortex.Herb-drug interactions: focus on metabolic enzymes and transporters.A Review of Alprazolam Use, Misuse, and Withdrawal.A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period.Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).Misuse of prescription drugs.Comparative evaluation of effect of preoperative alprazolam and diclofenac potassium on the success of inferior alveolar, Vazirani-Akinosi, and Gow-Gates techniques for teeth with irreversible pulpitis: Randomized controlled trial.Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner.Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report.Concentrations of alprazolam in blood from impaired drivers and forensic autopsies were not much different but showed a high prevalence of co-ingested illicit drugs.Does oral alprazolam affect ventilation? A randomised, double-blind, placebo-controlled trial.Pharmacodynamic response profiles of anxiolytic and sedative drugs.Use of conventional bioanalytical devices to automate DBS extractions in liquid-handling dispensing tips.Acid-catalysed hydrolysis and benzodiazepine-like properties of 5-(dialkylamino)- and 5-(alkylthio)-substituted 8-chloro-6-phenyl-6H-[1,2,4]triazolol[4,3-a][1,5]benzodiazepines in mice.Cross-conditional entropy and coherence analysis of pharmaco-EEG changes induced by alprazolam.FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.
P2860
Q28472957-4F076B8F-83D0-4F50-A0C3-CD1115FDE4F7Q30387331-3D4D08C3-8860-4E16-A02F-1A466C5F0BDEQ30403745-2EE1E639-06E1-47BD-B44A-3FDFBF574493Q30577525-48E79F30-1119-4936-80FC-64BD8D835423Q33148910-52EA785A-4C10-4781-A210-389F80D2278AQ33817870-0E65739E-1B89-4891-9B48-EFBD07872BDEQ34188636-45B20634-C62F-412E-BDC9-F5FAADCEE421Q34346469-2B368F5D-C9F6-4689-A5EF-CC5099F4F864Q34347407-5A049258-1E43-4357-9F0B-4F4FE0E6F988Q35079452-F8716C9C-9DF2-44D4-A9BF-204B23455DCCQ36548888-8FE8F717-CE25-4444-8994-6D13A82B00BFQ36873779-DD64EEAD-24DD-4BCF-967F-AD487B1D5A27Q36894491-B069D1D7-6318-48E9-A8BB-BF4923FABE40Q37023996-5E818C5D-05ED-4928-8CF2-AFEC36D0E388Q37100602-57B0032E-B707-48DB-9BBB-B53E249ACF6AQ37480332-44640C94-E122-4EDF-80DB-D52C442D6B5FQ37705765-1777332D-B3A4-4EA4-AFD9-055DC002DB85Q37964576-A6DCBBD6-5071-4E52-80AB-2C82CB39C02EQ38641123-84CAFA74-30E1-48B0-9BDF-8DE080718C52Q38843902-144C684D-A437-4B68-81FD-01D89B5B5690Q38925148-C9C6B043-9C82-4A30-A0A6-301467B7D4F0Q40966598-74BE5302-720F-4813-A8A9-E3F76D502576Q41109340-6C287906-03F5-4D4F-9D74-FC710381DFEAQ42155588-B02E2E45-ED5C-4FC8-BFBC-A1D95C629A07Q43670142-08BBA6AA-07F5-4FEA-8F8C-777D7186EA8FQ43791592-E1C4E8F8-DBA5-440C-89D3-2B713D1E07C0Q43954246-96F3C73A-0700-4599-AE32-74E9B47CCA40Q44495319-D29E5DE8-6A68-4C79-A6F8-13CEB54C2034Q46533428-220AC77A-44BA-417B-B8A2-1E6475CF329FQ48178645-5850ECF3-C431-44C0-9B1E-EB2E80FE5E56Q48221188-FE59DFBC-055C-4BCB-97B7-79DBF05918EFQ48404325-3A4A11BD-7A70-4DEC-999D-84611A44CA6EQ51486218-1F038856-BE20-4DB7-A77B-66F8BF27FDD7Q52205708-8CFE5010-D851-4BF3-A968-FBA057245355
P2860
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@ast
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@en
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@nl
type
label
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@ast
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@en
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@nl
prefLabel
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@ast
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@en
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@nl
P1476
Clinical pharmacokinetics of alprazolam. Therapeutic implications.
@en
P2093
Greenblatt DJ
P304
P356
10.2165/00003088-199324060-00003
P577
1993-06-01T00:00:00Z
P6179
1018231279